Fresenius Medical Care with a clear analyst picture, shares tracked on Xetra and in the DAX
26.06.2026 - 11:34:38 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 11:34.
Fresenius Medical Care (DE0005785802) is one of the established healthcare names in the DAX and trades primarily on Xetra in Frankfurt. The group offers global exposure to dialysis services and products, with the stock closely followed by international analysts according to current consensus data.
Analyst views on the dialysis group
Analyst coverage of Fresenius Medical Care is broad, reflecting its role as a large-cap healthcare player and pure-play dialysis specialist within the DAX environment. Houses tracked by platforms such as MarketScreener and finanzen.net report a mix of Buy, Hold and Sell ratings, with a clear majority in the neutral to positive camp based on the latest available data.
Price targets aggregated by these services typically span a corridor around the current quotation, indicating expectations for moderate potential rather than extreme scenarios in either direction. The dispersion of target prices illustrates differing views on reimbursement developments, efficiency measures and long-term demand trends for chronic kidney disease treatments within Europe and North America.
Consensus metrics and valuation context
Consensus statistics for Fresenius Medical Care usually include key ratios such as expected earnings per share, revenue growth and EBITDA margin for the next two to three fiscal years. In the healthcare equipment and services space, investors often compare these metrics with peers like Fresenius, B. Braun (non-listed) or international dialysis rival DaVita to gauge relative valuation and operational performance.
Valuation multiples such as forward price-earnings and enterprise-value-to-EBITDA ratios are used to benchmark the stock against the broader medical equipment and healthcare services sector. This provides a reference for how the market prices regulatory risk, labor cost pressures and demographic tailwinds from an aging population requiring renal replacement therapies.
All news and analysis on the Fresenius Medical Care shares
More background, ad-hoc disclosures and price data on Fresenius Medical Care can be found on the dedicated topic page and via the company’s investor relations hub.
How Fresenius Medical Care earns money
Fresenius Medical Care generates its revenue primarily from dialysis services and related products for patients with chronic kidney failure worldwide, operating a large network of dialysis clinics and supplying dialysis machines, dialyzers and consumables. The integrated model combines treatment provision with equipment manufacturing, creating scale advantages and recurring revenue streams in many markets.
Where the stock trades today
The Fresenius Medical Care shares (DE0005785802) trade in Frankfurt with Xetra as the main venue, and are part of the DAX large-cap index, providing liquidity and index visibility for international investors; current intraday price and market capitalization data are available via major quote platforms in euros.
Key data on the Fresenius Medical Care shares
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Trading venue: Xetra (Frankfurt)
- Price (as of 2026-06-26, 11:30): [latest quote] EUR
- Market cap: [current market capitalization] EUR (as of 2026-06-26)
- Sector / industry: Healthcare / Medical Equipment & Services
- Index membership: DAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Readers should conduct their own research or consult a qualified financial advisor before making investment decisions.
